

FORM PTO-1449  <b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	
				Group To Be Assigned	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*165	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 <sup>HER2</sup> Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)				
*166	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" <u>Cancer Research</u> 58:2825-2831 (July 1998)				
*167	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)				
*168	Bos, Johannes L., "A Target for Phosphoinositide 3-Kinase: Akt/PKB" <u>Trends Biochem. Sci.</u> 20:441-442 (Nov 1995)				
*169	Burden and Yarden., "Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis." <u>Neuron</u> 18(6):847-855 (Jun 1997)				
*170	Carraway and Cantley., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling." <u>Cell</u> 78:5-8 (Jul 15, 1994)				
*171	Carraway et al., "Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3" <u>J. Bio. Chem.</u> 270:7111-7116 (Mar 1995)				
*172	Carraway et al., "Neuregulin-2, A New Ligand of ErbB3/ErbB4-Receptor Tyrosine Kinases" <u>Nature</u> 387:512-516 (May 1997)				
*173	Carter et al., "Humanization of an Anti-p185 <sup>HER2</sup> Antibody For Human Cancer Therapy" <u>Proc. Natl. Acad. Sci. USA</u> 89:4285-4289 (May 1992)				
*174	Chang et al., "Ligands For ErbB-Family Receptors Encoded By a Neuregulin-Like Gene" <u>Nature</u> 387:509-512 (May 29, 1997)				
*175	Ching, K., "Role of c-erb B gene family in prostate cancer" <u>Dissertation Abstracts International</u> 55(11):4738-B (May 1995)				
*176	Cohen et al., "Expression Pattern of the neu (NGL) Gene-Encoded Growth Factor Receptor Protein (p185 <sup>neu</sup> ) in Normal and Transformed Epithelial Tissues of the Digestive Tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)				
*177	Connelly and Stern., "The Epidermal Growth Factor Receptor and the Product of the neu Protooncogene Are Members of a Receptor Tyrosine Phosphorylation Cascade." <u>Proc. Natl. Acad. Sci. USA</u> 87:6054-6057 (Aug 1990)				
*178	Craft et al., "A Mechanism For Hormone-Independent Prostate Cancer Through Modulation of Androgen Receptor Signaling by the HER-2/neu Tyrosine Kinase." <u>Nature Medicine</u> 5(3):280-285 (Mar 1999)				
*179	Curnow, R., "Clinical experience with CD64-directed immunotherapy. An overview" <u>Cancer Immunology and Immunotherapy</u> 45(3-4):210-215 (Nov-Dec 1997)				
*180	Curti, B., "Physical barriers to drug delivery in tumors" <u>Critical Reviews in Oncology-Hematology</u> 14(1):29-39 (Feb 1993)				
*181	D'Souza and Taylor-Papadimitriou., "Overexpression of ERBB2 in Human Mammary Epithelial Cells Signals Inhibition of Transcription of the E-Cadherin Gene." <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)				
*182	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)				
*183	Dermer, G., "Another anniversary for the war on cancer" <u>Biotechnology</u> 12:320 (1994)				
*184	Di Fiore et al., "erbB-2 Is A Potent Oncogene When Overexpressed In NIH/3T3 Cells." <u>Science</u> 237(4811):178-182 (Jul 10, 1987)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*185	Dillman, R., "Antibodies as cytotoxic therapy" <u>Journal of Clinical Oncology</u> 12(7):1497-1515 (Jul 1994)				
*186	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)				
*187	Drebin et al., "Inhibition of Tumor Growth By a Monoclonal Antibody Reactive With an Oncogene-Encoded Tumor Antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)				
*188	Drebin et al., "Monoclonal Antibodies Reactive With Distinct Domains of the neu Oncogene-Encoded p185 Molecule Exert Synergistic Anti-Tumor Effects In Vivo" <u>Oncogene</u> 2:273-277 (1988)				
*189	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)				
*190	Earp et al., "Heterodimerization and Functional Interaction Between EGF Receptor Family Members: A New Signaling Paradigm With Implications For Breast Cancer Research" <u>Breast Cancer Res and Treatment</u> 35:115-132 (1995)				
*191	Ezeh et al., "Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor- $\alpha$ and epidermal growth factor in vivo" <u>Journal of Neurobiology</u> 37(2):199-210 (Nov 5, 1998)				
*192	Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)				
*193	Fleiss, J.L. <u>Statistical Methods for Rates and Proportions</u> , 2nd edition, New York, NY:Wiley pps. 13-17 (1981)				
*194	Fukushige et al., "Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line." <u>Molecular &amp; Cellular Biology</u> 6(3):955-958 (Mar 1986)				
*195	Gemzar (gemcitabine HCL), "Product Information - PDR" (2000)				
*196	Gibson et al., "A novel method for real time quantitative RT-PCR" <u>Genome Research</u> 6(10):995-1001 (Oct 1996)				
*197	Goldman et al., "Heterodimerization of the erbB-1 and erbB-2 Receptors in Human Breast Carcinoma Cells: A Mechanism for Receptor Transregulation" <u>Biochemistry</u> 29(50):11024-11028 (1990)				
*198	Graus-Porta et al., "ErbB-2, The Preferred Heterodimerization Partner of All ErbB Receptors, Is a Mediator of Lateral Signaling." <u>EMBO Journal</u> 16(7):1647-1655 (1997)				
*199	Green et al., "Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector" <u>Cancer Research</u> 54(3):738-741 (Feb 1, 1994)				
*200	Grim et al., "erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells" <u>American Journal of Respiratory Cell &amp; Molecular Biology</u> 15(3):348-354 (Sep 1996)				
*201	Groenen et al., "Structure-Function Relationships for the EGF/TGF- $\alpha$ Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)				
*202	Gu et al., "Overexpression of her-2/neu in Human Prostate Cancer and Benign Hyperplasia." <u>Cancer Letters</u> 99:185-189 (1996)				
*203	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res</u> 3:21-31 (1988)				
*204	Gura, T., "Systems for identifying new drugs are often faulty" <u>Science</u> 278(5340):1041-1042 (Nov 7, 1997)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*205	Guy et al., "Expression of the neu Protooncogene in the Mammary Epithelium of Transgenic Mice Induces Metastatic Disease." <u>Proc. Natl. Acad. Sci. USA</u> 89(22):10578-10582 (Nov 15, 1992)				
*206	Hancock et al., "A Monoclonal Antibody Against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum Against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)				
*207	Harari et al., "Neuregulin-4: A Novel Growth Factor That Acts Through the ErbB-4 Receptor Tyrosine Kinase." <u>Oncogene</u> 18:2681-2689 (1999)				
*208	Harwerth et al., "Monoclonal Antibodies Against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)				
*209	Heid et al., "Real time quantitative PCR" <u>Genome Research</u> 6(10):986-994 (1996)				
*210	Holmes et al., "Identification of Heregulin, A Specific Activator of p185 <sup>erbB2</sup> " <u>Science</u> 256:1205-1210 (May 22, 1992)				
*211	Hudziak et al., "Increased Expression of the Putative Growth Factor Receptor p185 <sup>HER2</sup> Causes Transformation and Tumorigenesis of NIH 3T3 Cells." <u>Proc. Natl. Acad. Sci. USA</u> 84(20):7159-7163 (Oct 1987)				
*212	Hudziak et al., "p185 <sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular &amp; Cellular Biology</u> 9(3):1165-1172 (Mar 1989)				
*213	Hynes and Stern., "The Biology of erbB-2/neu/HER-2 and Its Role in Cancer." <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994)				
*214	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)				
*215	Jain, R., "Barriers to drug delivery in solid tumors" <u>Scientific American</u> 271(1):58-65 (Jul 1994)				
*216	James et al., "Phase II trial of the bispecific antibody MDX-H210 (anti-HER2/NEU X anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/NEU" <u>Proc. Annu. Meet. Soc. Clin. Oncol.</u> (Abstract No. 1681) 17:436a (1998)				
*217	James et al., "Phase II Trial of the Bispecific Antibody MDX-H210 (anti-Her2/Neu X anti-CD64) Combined With GM-CSF in Patients With Advanced Prostate and Renal Cell Carcinoma That Express Her2/Neu." <u>British Journal of Cancer</u> (Abstract #56) 78:19 (1998)				
*218	Jardines et al., "neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer" <u>Pathobiology</u> 61(5-6):268-282 (1993)				
*219	Jones et al., "Binding Interaction of the Heregulin $\beta$ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis" <u>Journal of Biological Chemistry</u> 273(19):11667-11674 (May 8, 1998)				
*220	Kabat. <u>Sequences of Proteins of Immunological Interest</u> , US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)				
*221	Kannan et al., "Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells" <u>Journal of Biological Chemistry</u> 272(6):3330-3335 (Feb 7, 1997)				
*222	Karunagaran et al., "ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer" <u>EMBO Journal</u> 15(2):254-264 (1996)				
*223	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)				
*224	Kern et al., "Inhibition of human lung cancer cell line growth by an anti-p185 <sup>HER2</sup> antibody" <u>American Journal of Respiratory Cell &amp; Molecular Biology</u> 9(4):448-454 (Oct 1993)				
Examiner		Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*225	Kern et al., "p185 <sup>neu</sup> Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)				
*226	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)				
*227	King et al., "EGF Binding to its Receptor Triggers a Rapid Tyrosine Phosphorylation of the erbB-2 Protein in the Mammary Tumor Cell Line SK-BR-3." <u>EMBO Journal</u> 7(6):1647-1651 (1988)				
*228	Klapper et al., "A Subclass of Tumor-Inhibitory Monoclonal Antibodies to ErbB-2/HER2 Blocks Crosstalk With Growth Factor Receptors" <u>Oncogene</u> 14:2099-2109 (1997)				
*229	Knox et al., "Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma" <u>Clinical Cancer Research</u> 2(3):457-470 (Mar 1996)				
*230	Kokai et al., "Synergistic Interaction of p185 <sup>c-neu</sup> and the EGF Receptor Leads to Transformation of Rodent Fibroblasts" <u>Cell</u> 58:287-292 (Jul 28, 1989)				
*231	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)				
*232	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" <u>FASEB Journal</u> (abstract #1470) 4(7):A1946 (1990)				
*233	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-gamma and Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (Program 1470, Joint Mtg of ASBMB & AAI in New Orleans, LA on June 4-7, 1990 poster)				
*234	Kraus et al., "Isolation and Characterization of ERBB3, A Third Member of the ERBB/Epidermal Growth Factor Receptor Family: Evidence for Overexpression in a Subset of Human Mammary Tumors" <u>Proc. Natl. Acad. Sci. USA</u> 86:9193-9197 (Dec 1989)				
*235	Krymskaya et al., "EGF Activates ErbB-2 and Stimulates Phosphatidylinositol 3-Kinase in Human Airway Smooth Muscle Cells." <u>Am. J. Physiol.</u> 276:L246-L255 (1999)				
*236	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular &amp; Cellular Biology</u> 11(2):979-986 (Feb 1991)				
*237	Lee et al., "Transforming Growth Factor $\alpha$ : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)				
*238	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)				
*239	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)				
*240	Lewis et al., "Differential Responses of Human Tumor Cell Lines to Anti-p185 <sup>HER2</sup> Monoclonal Antibodies." <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)				
*241	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)				
*242	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)				
*243	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)				
*244	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*245	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)				
*246	McKenzie et al., "Generation and Characterization of Monoclonal Antibodies Specific for the Human neu Oncogene Product, p185" <u>Oncogene</u> 4:543-548 (1989)				
*247	"Could Medarex's MAb be prostate cancer's Herceptin?" <u>Scrip</u> 2442:25 (Jun 2, 1999)				
*248	Medarex, Inc., "Medarex's HER-2 product show anti-cancer effects in phase II prostate and kidney studies" (company press release) (May 19, 1998)				
*249	Mendelsohn et al., "Receptor Blockade and Chemotherapy: A New Approach to Combination Cancer Therapy." <u>Annals of Oncology</u> (abstract #040) 7(Suppl. 1):22 (1996)				
*250	Morrissey et al., "Axon-Induced Mitogenesis of Human Schwann Cells Involves Heregulin and p185erbB2" <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)				
*251	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185neu" <u>Methods in Enzymology</u> 198:277-290 (1991)				
*252	Myers et al., "Intracellular antibody mediated down-regulation of p185erbB-2 expression in malignant prostatic cells" <u>Proceedings of the American Association for Cancer Research Annual Meeting</u> (Abstract #2334) 37:342 (1996)				
*253	Nagabhushan et al., "CWR22: The First Human Prostate Cancer Xenograft with Strongly Androgen-dependent and Relapsed Strains Both in Vivo and in Soft Agar" <u>Cancer Research</u> 56:3042-3046 (1996)				
*254	Nagy et al., "Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy" <u>Pathology Oncology Research</u> 5(4):255-271 (1999)				
*255	Norton, L., "Evolving Concepts in the Systemic Drug Therapy of Breast Cancer." <u>Seminars in Oncology</u> 24(4 Suppl 10):S10-3-S10-10 (Aug 1997)				
*256	Okabayashi et al., "Podofilox-induced regression of Shope papillomas may be independent of host immunity" <u>Journal of Investigative Dermatology</u> 101(6):852-857 (Dec 1993)				
*257	Okuda et al., "The cytostome of Trypanosoma cruzi epimastigotes is associated with the flagellar complex" <u>Experimental Parasitology</u> 92(4):223-231 (Aug 1999)				
*258	Olayoye et al., "ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent Upon Their Dimerization Partner." <u>Molecular &amp; Cellular Biology</u> 18:5042-5051 (Sep 1998)				
*259	Page et al., "A New Fluorometric Assay for Cytotoxicity Measurements In Vitro." <u>Int. J. Oncol.</u> 3:473-476 (1993)				
*260	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)				
*261	Pegram et al., "Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers" <u>Oncogene</u> 18:2241-2251 (1999)				
*262	Perrotta and Abuel, "Response of Chronic Relapsing ITP of 10 Years Duration to Rituximab" <u>Blood</u> (Abstract #3360) 92(10 Suppl. 1 Part 1-2):88b (Nov 1998)				
*263	Pietras et al., "Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells" <u>Oncogene</u> 9:1829-1838 (1994)				
*264	Plowman et al., "Heregulin Induces Tyrosine Phosphorylation of HER4/p180erbB4" <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					


FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*265	Plowman et al., "Ligand-Specific Activation of HER4/p180 <sup>erbB4</sup> , A Fourth Member of the Epidermal Growth Factor Receptor Family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)				
*266	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)				
*267	Raefsky et al., "Phase II Trial of Docetaxel and Herceptin as First- or Second-Line Chemotherapy for Women with Metastatic Breast Cancer Whose Tumors Overexpress HER2" <u>Proceedings of ASCO (Abstract #523)</u> 18:137a (1999)				
*268	Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review" <u>Gene</u> 159(1):19-27 (Jun 14, 1995)				
*269	Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987)				
*270	Ross et al., "HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence in Situ Hybridization" <u>Hum. Pathol.</u> 28(7):827-833 (July 1997)				
*271	Ross et al., "Prognostic Significance of HER-2/neu Gene Amplification Status by Fluorescence in Situ Hybridization of Prostate Carcinoma" <u>Cancer</u> 79(11):2162-2170 (June 1, 1997)				
*272	Sadasivan et al., "Overexpression of Her-2/Neu May Be An Indicator of Poor Prognosis in Prostate Cancer" <u>J. Urol.</u> 150:126-131 (Jul 1993)				
*273	Sarup et al., "Characterization of an Anti-P185 <sup>HER2</sup> Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)				
*274	Sato et al., "A Metastatic and Androgen-sensitive Human Prostate Cancer Model Using Intraprostatic Inoculation of LNCaP Cells in SCID Mice" <u>Cancer Research</u> 57:1584-1589 (1997)				
*275	Schaefer et al., "A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 is required for Transactivation of ErbB2" <u>Journal of Biological Chemistry</u> 274(2):859-866 (Jan 8, 1999)				
*276	Schaefer et al., "γ-Heregulin: A Novel Heregulin Isoform That is an Autocrine Growth Factor for the Human Breast Cancer Cell Line, MDA-MB-175" <u>Oncogene</u> 15:1385-1394 (1997)				
*277	Scher et al., "Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor α in the Progression of Prostatic Neoplasms" <u>Clinical Cancer Research</u> 1:545-550 (May 1995)				
*278	Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)				
*279	Scott et al., "p185 <sup>HER2</sup> Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)				
*280	Seifert et al., "Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity" <u>Annals of Pharmacotherapy</u> 28(9):1063-1072 (Sep 1994)				
*281	Shawver et al., "Ligand-Like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)				
*282	Sheng et al., "Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2" <u>J. Clin. Invest.</u> 99(9):2254-2259 (May 1997)				
*283	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)				
*284	Singal and Iliskovic, "Doxorubicin-induced cardiomyopathy" <u>New England J. of Medicine</u> 339(13):900-905 (Sep 24, 1998)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Kelsey et al.	
				Filing Date 27 Jun 2003	Group To Be Assigned
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*285	Singal et al., "Combination therapy with probucol prevents adriamycin-induced cardiomyopathy" <u>Journal of Molecular &amp; Cellular Cardiology</u> 27(4):1055-1063 (Apr 1995)				
*286	Skrepnik et al., "Recombinant Oncotoxin AR209 (anti-p185 <sup>erbB-2</sup> ) Diminishes Human Prostate Carcinoma Xenografts" <u>Journal of Urology</u> 161:984-989 (1999)				
*287	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)				
*288	Slamon et al., "Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)				
*289	Sliwkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" <u>Proceedings of the American Association for Cancer Research</u> (abstract only) 37:625-626 (Mar 1996)				
*290	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)				
*291	Stancovski et al., "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)				
*292	Stearns et al., "Workgroup 2: Human Xenograft Models of Prostate Cancer" <u>Prostate</u> 36:56-58 (1998)				
*293	Stern and Kamps., "EGF-Stimulated Tyrosine Phosphorylation of p185 <sup>neu</sup> : A Potential Model For Receptor Interactions." <u>EMBO Journal</u> 7(4):995-1001 (1988)				
*294	Sugarman et al., "Recombinant Human Tumor Necrosis Factor- $\alpha$ : Effects on Proliferation of Normal and Transformed Cells in Vitro" <u>Science</u> 230:943-945 (1985)				
*295	Tagliabue et al., "Selection of Monoclonal Antibodies Which Induce Internalization and Phosphorylation of p185 <sup>HER2</sup> and Growth Inhibition of Cells With HER2/NEU Gene Amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)				
*296	Tan et al., "Heregulin $\beta$ 1-Activated Phosphatidylinositol 3-Kinase Enhances Aggregation of MCF-7 Breast Cancer Cells Independent of Extracellular Signal-Regulated Kinase." <u>Cancer Research</u> , 59:1620-1625 (Apr 1999)				
*297	Vadlamudi et al., "Regulation of Cyclooxygenase-2 pathway by HER2 receptor" <u>Oncogene</u> 18:305-314 (1999)				
*298	Vitetta and Uhr, "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)				
*299	Wada et al., "Intermolecular Association of the p185 <sup>neu</sup> Protein and EGF Receptor Modulates EGF Receptor Function" <u>Cell</u> 61:1339-1347 (Jun 29, 1990)				
*300	Wainstein et al., "CWR22: Androgen-dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma" <u>Cancer Research</u> 54:6049-6052 (1994)				
*301	Weiner et al., "Expression of the neu Gene-encoded Protein (P185 <sup>neu</sup> ) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Research</u> 50(2):421-425 (Jan 15, 1990)				
*302	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996)				
*303	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59(1):46-52 (1991)				
*304	Wofsy et al., "Modification and Use of Antibodies to Label Cell Surface Antigens" <u>Selected Methods in Cellular Immunology</u> , Mishel and Schiigi, eds., San Francisco:WJ Freeman Co., Chapter 13, pps. 287-304 (1980)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Stephen M. Kelsey et al. Serial No.: To Be Assigned Filed: June 27, 2003 For: Treatment with Anti-ErbB2 Antibodies	Group Art Unit: To Be Assigned Examiner: To Be Assigned  <b>Express Mail No. EV 351 923 957 US</b> June 27, 2003  Anna Kan
--	---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR § 1.113, or a notice of allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR § 1.17(p) **or** a statement as specified in 37 CFR § 1.97(e), as checked below.

KEYBOARD(Enter Serial No.)

☐ **37 CFR §1.97(d)**

- after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) **and** a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR § 1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR § 1.704.

☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR § 1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in prior application Serial No. 10/268,501, filed October 10, 2002 and Serial No. 09/602,812 filed June 23, 2000 and relied upon in this application for an earlier filing date under 35 USC § 120.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-() " (nucleotide) and "BLAST Results B-1 - B-() " (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

KEYBOARD(Enter Serial No.)

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

By: \_\_\_\_\_

Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994

Date: June 27, 2003



09157

PATENT TRADEMARK OFFICE

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1467R2P2

Serial No.

To Be Assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Kelsey et al.

Filing Date

27 Jun 2003

Group

To Be Assigned

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	2002/0076695	20.06.02	Ross, J.			
	* 2	2002/0155527	24.10.02	Stuart et al.			
	* 3	4,753,894	28.06.88	Frankel et al.			
	* 4	4,935,341	19.06.90	Bargmann et al.			
	* 5	4,943,533	24.07.90	Mendelsohn et al.			
	* 6	4,968,603	06.11.90	Slamon et al.			
	* 7	4,975,278	04.12.90	Senter et al.			
	* 8	5,169,774	08.12.92	Frankel et al.			
	* 9	5,183,884	02.02.93	Kraus et al.			
	* 10	5,288,477	22.02.94	Bacus, S.			
	* 11	5,359,046	25.10.94	Capon et al.			
	* 12	5,367,060	22.11.94	Vandlen et al.			
	* 13	5,401,638	28.03.95	Carney et al.			
	* 14	5,464,751	07.11.95	Greene et al.			
	* 15	5,480,968	02.01.96	Kraus et al.			
	* 16	5,514,554	07.05.96	Bacus, S.			
	* 17	5,571,894	05.11.96	Wels, W. et al.			
	* 18	5,578,482	26.11.96	Lippman et al.			
	* 19	5,587,458	24.12.96	King, C. et al.			
	* 20	5,604,107	18.02.97	Carney et al.			
	* 21	5,641,869	24.06.97	Vandlen et al.			
	* 22	5,663,144	02.09.97	Greene et al.			
	* 23	5,677,165	14.10.97	de Boer et al.			
	* 24	5,677,171	14.10.97	Hudziak et al.			
	* 25	5,705,157	06.01.98	Greene, M. L.			
	* 26	5,720,937	24.02.98	Hudziak et al.			
	* 27	5,720,954	24.02.98	Hudziak et al.			
	* 28	5,725,856	10.03.98	Hudziak et al.			
	* 29	5,726,023	10.03.98	Cheever et al.			
	* 30	5,728,687	17.03.98	Bissery, M.			
	* 31	5,736,137	07.04.98	Anderson et al.			
	* 32	5,747,261	05.05.98	King et al.			
	* 33	5,770,195	23.06.98	Hudziak et al.			
	* 34	5,772,997	30.06.98	Hudziak et al.			
	* 35	5,776,427	07.07.98	Thorpe et al.			
	* 36	5,783,186	21.07.98	Arakawa et al.			

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  <b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned		
				Applicant Kelsey et al.			
				Filing Date 27 Jun 2003			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner	Initials	Document Number	Date	Name	Class	Subclass	Filing Date
		* 37 5,783,404	21.07.98	Koski, R.			
		* 38 5,801,005	01.09.98	Cheever et al.			
		* 39 5,804,396	08.09.98	Plowman			
		* 40 5,821,337	13.10.98	Carter et al.			
		* 41 5,824,311	20.10.98	Greene et al.			
		* 42 5,834,229	10.11.98	Vandlen et al.			
		* 43 5,837,243	17.11.98	Deo et al.			
		* 44 5,837,523	17.11.98	Greene et al.			
		* 45 5,840,525	24.11.98	Vandlen et al.			
		* 46 5,846,538	08.12.98	Cheever et al.			
		* 47 5,846,749	08.12.98	Slamon et al.			
		* 48 5,856,089	05.01.99	Wang et al.			
		* 49 5,856,110	05.01.99	Vandlen et al.			
		* 50 5,859,206	12.01.99	Vandlen et al.			
		* 51 5,869,445	09.02.99	Cheever et al.			
		* 52 5,876,712	02.03.99	Cheever et al.			
		* 53 5,877,305	02.03.99	Huston et al.			
		* 54 5,882,864	16.03.99	An et al.			
		* 55 5,908,835	01.06.99	Bissery, M.			
		* 56 5,910,486	08.06.99	Curriel et al.			
		* 57 5,922,845	13.07.99	Deo et al.			
		* 58 5,925,519	20.07.99	Jensen et al.			
		* 59 5,939,531	17.08.99	Wels et al.			
		* 60 5,968,511	19.10.99	Akita et al.			
		* 61 5,977,322	02.11.99	Marks et al.			
		* 62 5,985,553	16.11.99	King et al.			
		* 63 5,994,071	30.11.99	Ross et al.			
		* 64 6,015,567	18.01.00	Hudziak et al.			
		* 65 6,028,059	22.02.00	Curriel et al.			
		* 66 6,054,297	25.04.00	Carter et al.			
		* 67 6,054,561	25.04.00	Ring, D. B.			
		* 68 6,096,873	01.08.00	Schaefer et al.			
		* 69 6,123,939	26.09.00	Shawver et al.			
		* 70 6,165,464	26.12.00	Hudziak et al.			
		* 71 6,270,765	07.08.01	Deo et al.			
		* 72 6,333,348	25.12.01	Vogel et al.			
Examiner					Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449  <b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1467R2P2	Serial No. To Be Assigned
		Applicant Kelsey et al.	
		Filing Date 27 Jun 2003	Group To Be Assigned

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
	* 73	6,358,682	19.03.02	Jaffee et al.		
	* 74	6,395,272	28.05.02	Deo et al.		
	* 75	6,403,630	11.06.02	Dannenberg et al.		
	* 76	6,417,168	09.07.02	Greene et al.		
	* 77	6,458,356	01.10.02	Arakawa et al.		
	* 78	6,512,097	28.01.03	Marks et al.		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes      No	
	* 79	0,599,274 A1	01.06.94	EPO			
	* 80	1,006,194	07.06.00	EPO			
	* 81	332,865	20.09.89	EPO			
	* 82	412,116	29.11.95	EPO			
	* 83	444,181	31.10.01	EPO			
	* 84	494,135	10.04.96	EPO			
	* 85	502,812	14.08.96	EPO			
	* 86	554,441	27.01.99	EPO			
	* 87	616,812 A1	28.09.94	EPO			
	* 88	656,367	07.06.95	EPO			
	* 89	711,565	26.08.98	EPO			
	* 90	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)			
	* 91	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)			
	* 92	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 93	5-117165	14.05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 94	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 95	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 96	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 97	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 98	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)			
	* 99	WO 00/61145	19.10.00	PCT			
	*100	WO 00/61185	19.10.00	PCT			
	*101	WO 00/69460	23.11.00	PCT			
	*102	WO 00/78347	28.12.00	PCT			
	*103	WO 01/00238 A1	04.01.01	PCT			
	*104	WO 01/00244 A2	04.01.01	PCT			
	*105	WO 01/05425	25.01.01	PCT			

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  <b>U.S. Dept. of Commerce</b> <b>Patent and Trademark Office</b>			Atty Docket No. P1467R2P2		Serial No. To Be Assigned	
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)			Applicant Kelsey et al.			
			Filing Date 27 Jun 2003		Group To Be Assigned	
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes    No
	*106 WO 01/09187	08.02.01	PCT			
	*107 WO 01/15730	08.03.01	PCT			
	*108 WO 01/20033	22.03.01	PCT			
	*109 WO 01/21192	29.03.01	PCT			
	*110 WO 01/32155	10.05.01	PCT			
	*111 WO 87/07646	17.12.87	PCT			
	*112 WO 89/06692	27.07.89	PCT			
	*113 WO 89/10412	02.11.89	PCT			
	*114 WO 90/14357	29.11.90	PCT			
	*115 WO 91/02062	21.02.91	PCT			
	*116 WO 91/05264	18.04.91	PCT			
	*117 WO 92/10573	25.06.92	PCT			
	*118 WO 92/20798	26.11.92	PCT			
	*119 WO 93/03741	04.03.93	PCT			
	*120 WO 93/12220	24.06.93	PCT			
	*121 WO 93/16185	19.08.93	PCT			
	*122 WO 93/21232	28.10.93	PCT			
	*123 WO 93/21319	28.10.93	PCT			
	*124 WO 94/00136	06.01.94	PCT			
	*125 WO 94/22478	13.10.94	PCT			
	*126 WO 94/28127	08.12.94	PCT			
	*127 WO 95/16051	15.06.95	PCT			
	*128 WO 95/17507	29.06.95	PCT			
	*129 WO 95/28485	26.10.95	PCT			
	*130 WO 96/07321	14.03.96	PCT			
	*131 WO 96/16673	06.06.96	PCT			
	*132 WO 96/18409	20.06.96	PCT			
	*133 WO 96/40789	19.12.96	PCT			
	*134 WO 97/00271	03.01.97	PCT			
	*135 WO 97/04801	13.02.97	PCT			
	*136 WO 97/20858	12.06.97	PCT			
	*137 WO 97/27848	07.08.97	PCT			
	*138 WO 97/35885	02.10.97	PCT			
	*139 WO 97/38731	23.10.97	PCT			
	*140 WO 98/02463	22.01.98	PCT			
	*141 WO 98/02540	22.01.98	PCT			
Examiner				Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

FORM PTO-1449  <b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2P2	Serial No. To Be Assigned		
				Applicant Kelsey et al.			
				Filing Date 27 Jun 2003	Group To Be Assigned		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes      No	
	*142 WO 98/02541	22.01.98	PCT				
	*143 WO 98/16628	23.04.98	PCT				
	*144 WO 98/17797	30.04.98	PCT				
	*145 WO 98/18489	07.05.98	PCT				
	*146 WO 98/33914	06.08.98	PCT				
	*147 WO 98/45479	15.10.98	PCT				
	*148 WO 99/31140	24.06.99	PCT				
	*149 WO 99/39729	12.08.99	PCT				
	*150 WO 99/55367	04.11.99	PCT				
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	*151 Aasland et al., "Expression of Oncogenes in Thyroid Tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)						
	*152 Agus et al., "Differential Anti-Tumor Effects of Targeting Distinct Epitopes of the Her-2/neu Extracellular Domain in Xenograft Models of Prostate Cancer." <u>Proceedings of the American Association for Cancer Research Annual Meeting</u> (Abstract #4570) 41:719 (Mar 2000)						
	*153 Agus et al., "Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-Dependent and -Independent Human Xenograft Models" <u>Cancer Research</u> 59:4761-4764 (1999)						
	*154 Ahmed et al., "A New Rapid and Simple Non-Radioactive Assay to Monitor and Determine the Proliferation of Lymphocytes: An Alternative to [ <sup>3</sup> H]Thymidine Incorporation Assay." <u>J. Immunol. Methods</u> 170:211-224 (1994)						
	*155 Akiyama et al., "Tumor Promoter and Epidermal Growth Factor Stimulate Phosphorylation of the c-erbB-2 Gene Product in MKN-7 Human Adenocarcinoma Cells" <u>Molecular &amp; Cellular Biology</u> 8(3):1019-1026 (Mar 1988)						
	*156 American Cancer Society Textbook of Clinical Oncology, Murphy et al., 2nd edition, Atlanta:American Cancer Society pps. 126-127 (1995)						
	*157 Arteaga et al., "p185 <sup>c-erbB-2</sup> Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)						
	*158 Baca et al., "Antibody Humanization Using Monovalent Phage Display" <u>Journal of Biological Chemistry</u> 272(16):10678-10684 (1997)						
	*159 Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)						
	*160 Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)						
	*161 Baselga and Mendelsohn, "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)						
	*162 Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAB) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)						
	*163 Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implications" <u>Oncology</u> (Supplement No. 2) 11(3):43-48 (March 1997)						
	*164 Baselga et al., "Monoclonal Antibodies Directed Against Growth Factor Receptors Enhance the Efficacy of Chemotherapeutic Agents." <u>Annals of Oncology</u> (abstract #010) 5(Suppl. 5) (1994)						
Examiner				Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							